Market Overview

Verastem Files for Orphan Disease Status in US and EU for VS-6063 in Mesothelioma

Verastem (NASDAQ: VSTM) announced the filing of
orphan drug designation for VS-6063.

Verastem is seeking orphan drug designation in the US and the EU for the
use of VS-6063 in mesothelioma. VS-6063 is anticipated to enter a
potentially pivotal study in mesothelioma midyear 2013.

Orphan designation grants US market exclusivity to a drug for the
treatment of a specified condition for a period of seven years following
FDA marketing approval and 10 years of market exclusivity in member
states of the EU if received. Additional potential benefits of orphan

See full press release

Posted-In: News Guidance Management

 

Related Articles (VSTM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters